Literature Review: Role of Budesonide with Surfactant on Preterm Infants
Keywords:
Budesonide, surfactant therapy, respiratory distress syndrome, preterm infants, bronchopulmonary dysplasia, inflammationAbstract
This review analyzes the advocacy of budesonide-booster and surfactant in treating respiratory disorders in preterm neonates. Premature labor leads to respiratory distress syndrome [RDS] because of inadequate surfactant production and immature lungs, which in turn raises the probability of chronic lung disorders like BPD. However, while promoting lung function and oxygenation as provided in exogenous surfactant therapy is effective, it does not meet the processes causing inflammation to reduce pulmonary complications in the long run. Budesonide, a highly selective anti-inflammatory glucocorticosteroid, can be used as an adjuvant to surfactant treatment because of its ability to act on the lungs with minimal systemic effects directly. Studies from PubMed and Embase also show that when combined, budesonide and surfactant have beneficial effects in decreasing the severity of RDS, enhancing lung function, and reducing the prevalence of BPD in premature infants. However, these promising results should be further investigated in terms of the determination of optimal dosing, administration time, and therapeutic application concerning safety issues in the long term. This combined strategy has valuable prospects for enhancing the respiratory prognosis in premature newborns.
References
F. B. Safa, M. Noorishadkam, M. H. Lookzadeh, S. R. Mirjalili, and S. Ekraminasab, “Budesonide and Surfactant Combination for Treatment of Respiratory Distress Syndrome in Preterm Neonates and Evaluation Outcomes,” Journal of Clinical Neonatology/Journal of clinical neonatology, vol. 12, no. 4, pp. 135–141, Jan. 2023, doi: https://doi.org/10.4103/jcn.jcn_52_23.
M. Heo and G. W. Jeon, “View of Intratracheal administration of budesonide with surfactant in very low birth weight infants to prevent bronchopulmonary dysplasia,” Turkjpediatr.org, 2024. https://turkjpediatr.org/article/view/483/482 [accessed Dec. 18, 2024].
L. Moschino et al., “Intra?tracheal surfactant/budesonide versus surfactant alone: Comparison of two consecutive cohorts of extremely preterm infants,” Pediatric Pulmonology, May 2021, doi: https://doi.org/10.1002/ppul.25415.
A. Marzban, S. Mokhtari, P. Tavakkolian, R. Mansouri, N. Jafari, and A. Maleki, “The impact of combined administration of surfactant and intratracheal budesonide compared to surfactant alone on bronchopulmonary dysplasia [BPD] and mortality rate in preterm infants with respiratory distress syndrome: a single-blind randomized clinical trial,” BMC pediatrics, vol. 24, no. 1, Apr. 2024, doi: https://doi.org/10.1186/s12887-024-04736-9.
Z. Yi et al., “A systematic review and meta-analysis of pulmonary surfactant combined with budesonide in the treatment of neonatal respiratory distress syndrome,” Translational pediatrics, vol. 11, no. 4, pp. 526–536, Apr. 2022, doi: https://doi.org/10.21037/tp-22-8.
B. Deliloglu, F. Tuzun, M. M. Cengiz, H. Ozkan, and N. Duman, “Endotracheal Surfactant Combined With Budesonide for Neonatal ARDS,” Frontiers in Pediatrics, vol. 8, May 2020, doi: https://doi.org/10.3389/fped.2020.00210.
M. Gharehbaghi, S. Ganji, and M. Mahallei, “A Randomized Clinical Trial of Intratracheal Administration of Surfactant and Budesonide Combination in Comparison to Surfactant for Prevention of Bronchopulmonary Dysplasia,” Oman Medical Journal, vol. 36, no. 4, pp. e289–e289, Jul. 2021, doi: https://doi.org/10.5001/omj.2021.84.
M. Shehab, E. E. Elkhawaga, L. Elsayed, and M. Abdo, “Intratracheal Administration of Budesonide with Surfactant in Very Low Birth Weight Infants to Prevent Bronchopulmonary Dysplasia,” Zagazig university medical journal, vol. 0, no. 0, Sep. 2023, doi: https://doi.org/10.21608/zumj.2023.233021.2870.
B. J. Manley et al., “Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial,” vol. 24, no. 1, May 2023, doi: https://doi.org/10.1186/s13063-023-07257-5.
C. T. McEvoy et al., “Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns [SASSIE],” Pediatric Research, vol. 88, no. 4, pp. 629–636, Feb. 2020, doi: https://doi.org/10.1038/s41390-020-0792-y.
M. M. Gharehbaghi, M. Mhallei, S. Ganji, and S. Yasrebinia, “The efficacy of intratracheal administration of surfactant and budesonide combination in the prevention of bronchopulmonary dysplasia,” Journal of Research in Medical Sciences, vol. 26, no. 1, pp. 31–31, Jan. 2021, doi: https://doi.org/10.4103/jrms.jrms_106_19.
C. Zhang, “Evaluation of the Efficacy of Budesonide Combined with Pulmonary Surfactants on the Neonatal Respiratory Distress Syndrome by Pulmonary Ultrasonography,” Scientific Programming, vol. 2021, pp. 1–6, Nov. 2021, doi: https://doi.org/10.1155/2021/2329524.
N. H. Hillman, L. Abugisisa, and E. Royse, “Dose of budesonide with surfactant affects lung and systemic inflammation after normal and injurious ventilation in preterm lambs,” 2020. https://www.nature.com/articles/s41390-020-0809-6
C. D. Anderson, T. B. Kothe, and J. B. Josephsen, “Budesonide mixed with surfactant did not affect neurodevelopmental outcomes at 6 or 18 months corrected age in observational cohorts,” 2021. https://www.nature.com/articles/s41372-021-01066-x
A. O. Gunes and A. Bozkaya, “Endotracheal Surfactant and Budesonide Combination Therapy in Neonatal Acute Respiratory Distress Syndrome due to Late-Onset Sepsis,” Archives of Iranian Medicine, vol. 27, no. 10, pp. 573–579, Oct. 2024, doi: https://doi.org/10.34172/aim.31725.
Y. Yao, G. Zhang, F. Wang, and M. Wang, “Efficacy of budesonide in the prevention and treatment of bronchopulmonary dysplasia in premature infants and its effect on pulmonary function,” American Journal of Translational Research, vol. 13, no. 5, p. 4949, May 2021, Accessed: Dec. 18, 2024. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC8205685/
N. H. Hillman et al., “Surfactant plus budesonide decreases lung and systemic responses to injurious ventilation in preterm sheep,” American Journal of Physiology-lung Cellular and Molecular Physiology, vol. 318, no. 1, pp. L41–L48, Jan. 2020, doi: https://doi.org/10.1152/ajplung.00203.2019.
M. S. Elfarargy, G. M. Al-Ashmawy, S. M. Abu-Risha, and H. A. Khattab, “Inhaled Budesonide in Neonatal Respiratory Distress Syndrome of Near-Term Neonates: A Randomized, Placebo-Controlled Trial,” The Journal of Pediatric Pharmacology and Therapeutics, vol. 27, no. 1, pp. 38–44, Dec. 2021, doi: https://doi.org/10.5863/1551-6776-27.1.38.
N. H. Hillman et al., “Postnatal budesonide improved lung function in preterm lambs exposed to antenatal steroids and chorioamnionitis,” Pediatric Research, vol. 96, no. 3, pp. 678–684, Feb. 2024, doi: https://doi.org/10.1038/s41390-024-03092-9.
P. L. Ballard, D. Torgerson, and R. Wadhawan, “Blood metabolomics in infants enrolled in a dose escalation pilot trial of budesonide in surfactant,” www.nature.com/, 2021. https://www.nature.com/articles/s41390-020-01343-z
A. Sett, C. C. Roehr, and B. J. Manley, “Surfactant as a drug carrier,” Seminars in Fetal & Neonatal Medicine, vol. 28, no. 6, p. 101499, Dec. 2023, doi: https://doi.org/10.1016/j.siny.2023.101499.
K. Vemireddy, N. Panigrahy, V. Jamalpuri, Venkatlakshmi, and D. K. Chirla, “Comparison Of Intratracheal Administration Of Surfactant With Or Without Budesonide To Prevent Bronchopulmonary Dysplasia – A Parallel Randomized Pilot Study,” Research Square [Research Square], Feb. 2022, doi: https://doi.org/10.21203/rs.3.rs-1339070/v1.
R. Zecchi et al., “Surfactant-Assisted Distal Pulmonary Distribution of Budesonide Revealed by Mass Spectrometry Imaging,” Pharmaceutics, vol. 13, no. 6, p. 868, Jun. 2021, doi: https://doi.org/10.3390/pharmaceutics13060868.
L. Shi, G. Shan, X. Zhang, B. Zhang, A. Zhang, and Z. Liu, “Original Article Comparison of therapeutic effects of budesonide and ambroxol combined with bovine pulmonary surfactant on neonatal respiratory distress syndrome,” Int J Clin Exp Med, vol. 13, no. 8, pp. 5754–5762, 2020, Accessed: Dec. 18, 2024. [Online]. Available: https://e-century.us/files/ijcem/13/8/ijcem0113632.pdf
B. Baer, L. McCaig, C. Yamashita, and R. Veldhuizen, “Exogenous Surfactant as a Pulmonary Delivery Vehicle for Budesonide In Vivo,” Lung, vol. 198, no. 6, pp. 909–916, Oct. 2020, doi: https://doi.org/10.1007/s00408-020-00399-2.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal of Sciences: Basic and Applied Research (IJSBAR)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who submit papers with this journal agree to the following terms.
